Form 4: UTHR Director Sells Shares Under 10b5-1 Plan

Christopher Causey, a Director at United Therapeutics Corp, executed a pre-planned sale of 1,000 common shares following the exercise of stock options.

Summary

• Christopher Causey, a Director of United Therapeutics Corp (UTHR), exercised 1,000 stock options at a price of $119.76 per share.
• Concurrently, Mr. Causey sold 1,000 shares of common stock at a price of $520 per share.
• These transactions were executed on February 25, 2026.
• The exercise and subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan established on September 30, 2025.
• Following these transactions, Mr. Causey directly owns 4,190 shares of common stock and 6,320 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While a director selling shares can sometimes be seen negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling, and the significant profit from option exercise highlights the company's stock performance.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, undisclosed information.
• The exercise price of the options ($119.76) compared to the sale price ($520) demonstrates significant value creation for the director from their equity compensation.

Negatives

• A director selling shares, even under a 10b5-1 plan, represents a reduction in their direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for executives and directors managing their personal portfolios and liquidity. These pre-scheduled sales are generally viewed as less indicative of management's immediate sentiment about the company's prospects compared to unscheduled, open-market sales.

Related Party Transactions

• Christopher Causey, a Director of United Therapeutics Corp, engaged in an exercise of stock options and subsequent sale of common stock, which constitutes a related party transaction as an insider dealing.

Stakeholder Impact

• Shareholders: The sale by a director, even if pre-planned, slightly reduces insider ownership, which some investors might view as a minor negative. However, the 10b5-1 plan context generally prevents significant negative interpretation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (option exercise and sale) by a director under a Rule 10b5-1 plan. This type of transaction is generally not indicative of new material information about the company's future prospects and therefore does not warrant a change in investment recommendation based solely on this filing. The significant profit realized by the director from the option exercise reflects past stock performance, but the sale itself is a personal liquidity event.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transaction, Equity Compensation